



REPORT OF THE TRUSTEES AND
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023
FOR PLANETS CANCER CHARITY

REGISTERED CHARITY NUMBER: 1175572

REPORT OF THE TRUSTEES

FOR THE YEAR ENDED 31 MARCH 2023

The trustees present their report with the financial statements of the charity for the year ended 31 March 2023.

The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

About PLANETS

PLANETS Cancer Charity helps patients with pancreatic, liver, colorectal, gastric, oesophageal and neuroendocrine cancer by funding patient support groups, innovative treatments and research. Since 2011 we have raised just under £2 million.

PLANETS is dedicated to serving the needs of our regional population which extends from Lyme Regis to Bognor Regis and provides specialist cancer services to the four million people who live across Hampshire, Wiltshire, Dorset, the Isle of Wight, the Channel Islands and West Sussex.

Vision

Transforming cancer care in the south through our 'family' of patients, supporters and healthcare professionals to deliver world leading innovation, research and support for those affected by cancer within the PLANETS community.

Our ethos is one of inclusivity, where doctors, nurses, patients, family members, other healthcare workers and supporters all recognise each other's contributions and work together with a shared vision.

In line with our vision and objectives, we will ensure that:

- Patients and their families receive outstanding support

– published in leading international medical journals – by drastically reducing recurrence rates for these aggressive cancers.

- Funded full-time pancreatic and neuroendocrine tumour PhD and MD researchers to work with the clinician scientists in Southampton's world leading cancer immunology research department.
- Helped to achieve European Neuroendocrine Cancer Centre of Excellence status (2016).
- Funded Hyperthermic intraperitoneal chemotherapy (HiPeC) at University Hospital Southampton NHS Foundation Trust (UHS), one of the first centres in the UK to use this treatment.
- Funded a full-time neuroendocrine tumour dietitian, one of the first in the UK, specialising in helping patients from across the region, with these rare cancers with serious effects on the digestive system.
- Invested in a range of small projects supporting treatment and care for PLANETS cancer patients from ultrasound machines, 3D anatomical models for outpatients, radioisotope delivery equipment, DAB radios for radiotherapy bunkers, psychotherapy sessions for patients struggling with their cancer diagnosis and targeted fitness support for cancer patients among many other small but significant and important items to assist cancer patients on their journey.

All of this has brought our local cancer community together.

In line with our charitable goals, all funds we raise are being channelled into new treatments that are directly saving lives, patient support initiatives which change the lives of those with cancer and research projects which may one day help us find new treatments such as immunotherapy for current and future patients.

Year in review – April 2022 to 31 March 2023

This has been a really important transitional year for the charity as we continue to establish ourselves on a long-term, sustainable footing as an independent charity. Previously we managed with volunteer support, rather than staff on the payroll. We have now moved from this arrangement, through a period of ad hoc payments for staff, through to paid employment for our CEO and director of operations. This has been an essential part of our charities journey and will allow us to provide a better, more comprehensive and professional service in the future. Whilst we have been extremely successful for a volunteer led charity, the impact on work life balance for our volunteer staff has been enormous as they try to balance their charity commitments, with family life and other paid employment. This move to paid staff, has coincided with the resumption of many normal fundraising activities, which were heavily curtailed during the Covid 19 pandemic. Establishing ourselves on this more formal, professional basis will enable the further growth of the charity as we seek to achieve our charitable goals.

The development of our charity has also seen a greater involvement of our Board of Trustees, in particular with oversight of financial expenditure with establishment of a finance committee to ensure close review of accounts on a monthly basis. This is an essential part of our governance structure.





Later in May we reported the start of the ELECTRA trial. This is the first national clinical trial using PLANETS funded intraoperative electron beam radiotherapy (IORT) via the Mobetron machine at University Hospital Southampton. People undergoing surgery for rectal cancer that has spread into the pelvis have since been invited to join the trial, which aims to see whether the treatment can improve surgical outcomes. The trial, led by PLANETS team member Alex Mirnezami, professor of surgical oncology and consultant colorectal surgeon at UHS, is funded by Mobetron manufacturer IntraOp and endorsed by Cancer Research UK with funding support from PLANETS.



In July, PLANETS warned many patients are unable to secure affordable travel insurance – or even any at all – and in conjunction with the national Cancer52 charity embarked on a media campaign and petition to tackle the issue. The petition – launched on Change.org – has since secured more than 130,000 signatures. Subsequently PLANETS wrote to the Financial Conduct Authority (FCA), the UK's financial regulator which oversees the travel insurance industry, to highlight the issues. This has resulted in PLANETS being asked to collaborate with the FCA, as well as the Association of British Insurers (ABI), to support a review and put forward proposals to overcome some of the challenges being faced. This work has received significant national media attention and is ongoing into the current year.

PLANETS thanked its supporters after completing an 8 year, £1 million fundraising campaign and making the final payment in January 2022 for the pioneering intraoperative electron beam radiotherapy machine Mobetron at University Hospital Southampton. It remains the only centre in the country to offer the treatment. This uses high energy electron beams delivered with precision to a very specific location inside the body immediately after a cancer has been removed. Around 190 patients from across the UK, have been treated with the technology in Southampton since its introduction with impressive results, reported in the British Journal of Surgery and World Journal of Surgical Oncology.

FINANCIAL REVIEW

Reserves policy

For 2022/23 the Charity's reserves policy, which is reviewed each year, was to retain an amount of unrestricted reserves which was enough to cover 1 year of expenditure £208,621. We aim to spend income within 36 months of receipt. Where sums are set aside towards the cost of a project or piece of equipment, we retain those sums in a designated fund until enough money is available to meet the full cost of the project.

FUTURE PLANS

We need to raise £1.5 million over the next five years to achieve our goals of providing £250,000 for patient support, £500,000 for research into PLANETS cancers and £750,000 for innovative treatments.

In the current, cost-cutting NHS environment, research and innovation is in danger of being side-lined. The PLANETS team aim to ensure that patients across our region and further afield still have access to the best available care.

A NET dietitian has been jointly funded with the Robert White Trust to help patients across the Wessex NET group area, including attendance at the weekly NET MDT as well as at the monthly NET clinics in Dorchester, Poole, Bournemouth, Southampton, and Portsmouth. The role is also designed to include education of patients and other members of the clinical service around the region about dietary management of NET patients. (Funding started in May 2021 at a cost of £5k per month) our liability for this ends July 2023.

We have introduced a formal process for inviting application for funding projects for investment in patient support projects, research or therapeutics.

We are committed to funding several further projects including:

- The REMACS study. This is a national study and we are co-funding a PhD researcher looking at quality of life and outcome measures after a range of different surgical techniques for managing advanced pelvic cancers, such as recurrent rectal cancer.
- Ongoing research into predictive models for identifying people at risk of developing pancreatic cancer, using genomic data from cancer patients and the UK biobank as well as clinical risk factors. We are committed to funding laboratory costs for a PhD researcher.
- Conversion of a room within the gastroenterology and hepatology ward footprint at UHS into a wellbeing room for PLANETS patients. This will provide a quiet space for private conversations as well as the opportunity for patients to relax or exercise using weights or cardio equipment to maintain their physical condition.
- A peptide receptor radionuclide therapy (PRRT) manual dose injector at Dorset hospital. This is a new cancer treatment service and the equipment is designed to reduce radiation exposure when treating patients with targeted radioisotope therapy.

Following our initial request for applications for funding we have several exciting new possibilities, which require additional information before we can decide whether to commit to supporting them,

Trustees

Dr B Stedman

Professor A Mirnezami

Professor T Underwood

Mr C Hoyland

Miss V Caine

Miss R M H Willrich

Miss E L Medway


Mr R J Griffiths (resigned 31.1.2022)

Independent Examiner

S Mackie, FCA, Morris Crocker, Chartered Accountants

Station House, North Street, Havant, Hampshire, PO9 1QU

Approved by order of the board of trustees on 15th November 2023 and signed on its behalf by:

A handwritten signature in black ink, appearing to be 'Dr B Stedman', written over a dotted line.

Dr B Stedman - Trustee

PLANETS CANCER CHARITY

STATEMENT OF FINANCIAL ACTIVITIES

FOR THE YEAR ENDED 31 MARCH 2023

PLANETS CANCER CHARITY
STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2023

	Notes	Unrestricted funds £	Restricted funds £	2023 Total funds £	2022 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	2	100,382	-	100,382	452,582
Charitable activities	4				
Charitable activities		1,325	-	1,325	1,118
Other trading activities	3	71,896	-	71,896	14,532
Total		<u>173,603</u>	<u>-</u>	<u>173,603</u>	<u>468,232</u>
EXPENDITURE ON					
Raising funds	5	30,524	-	30,524	25,112
Charitable activities	6				
Charitable activities		178,097	-	178,097	294,123
Total		<u>208,621</u>	<u>-</u>	<u>208,621</u>	<u>319,235</u>
NET INCOME/(EXPENDITURE)		(35,018)	-	(35,018)	148,997
RECONCILIATION OF FUNDS					
Total funds brought forward		298,287	17,102	315,389	168,568
TOTAL FUNDS CARRIED FORWARD		<u>263,269</u>	<u>17,102</u>	<u>280,371</u>	<u>317,565</u>

PLANETS CANCER CHARITY

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2023

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight line basis over the period of the lease.

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 MARCH 2023

3. OTHER TRADING ACTIVITIES

	2023 £	2022 £
Fundraising events	<u>71,896</u>	<u>14,532</u>

4. INCOME FROM CHARITABLE ACTIVITIES

	Activity Charitable activities	2023 £	2022 £
Merchandising		<u>1,325</u>	<u>1,118</u>

5. RAISING FUNDS

Raising donations and legacies

	2023 £	2022 £
Fundraising expenditure	<u>30,524</u>	<u>25,112</u>

6. CHARITABLE ACTIVITIES COSTS

	Direct Costs £	Support costs (see note 7) £	Totals £
Charitable activities	<u>169,469</u>	<u>8,628</u>	<u>178,097</u>

7. SUPPORT COSTS

	Management £	Finance £	Governance costs £	Totals £
Charitable activities	<u>5,056</u>	<u>164</u>	<u>3,408</u>	<u>8,628</u>

Support costs, included in the above, are as follows:

Management

	2023 Charitable activities £	2022 Total activities £
Computer costs	3,356	1,972
Training costs	263	1,384
Postage and stationery	1,437	269
Sundries	-	131
	<u>5,056</u>	<u>3,756</u>

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 MARCH 2023

10. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued

	Unrestricted funds £	Restricted funds £	Total funds £
Raising funds	25,112	-	25,112
Charitable activities			
Charitable activities	83,020	211,103	294,123
Total	108,132	211,103	319,235
NET INCOME/(EXPENDITURE)	337,448	(188,451)	148,997
Transfers between funds	(145,098)	145,098	-
Net movement in funds	192,350	(43,353)	148,997
RECONCILIATION OF FUNDS			
Total funds brought forward	108,113	60,455	168,568
TOTAL FUNDS CARRIED FORWARD	300,463	17,102	317,565

11. STOCKS

	2023 £	2022 £
Stocks	4,451	2,514

12. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023 £	2022 £
Trade debtors	650	-

13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023 £	2022 £
Other creditors	1,350	1,585

14. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Unrestricted funds £	Restricted funds £	2023 Total funds £	2022 Total funds £
Current assets	264,619	17,102	281,721	319,150
Current liabilities	(1,350)	-	(1,350)	(1,585)
	263,269	17,102	280,371	317,565

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 MARCH 2023

15. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	445,580	(108,132)	337,448
Restricted funds			
IORT fund	11,550	(211,103)	(199,553)
R&D fund	11,102	-	11,102
	<u>22,652</u>	<u>(211,103)</u>	<u>(188,451)</u>
TOTAL FUNDS	<u>468,232</u>	<u>(319,235)</u>	<u>148,997</u>

IORT fund - Planets hold a contract to pay the hospital monthly instalments for the lease purchase of the IORT machine. Planets does not own it as it is gifted to the hospital. This lease was fully paid off during the financial year.

REMACS R&D - reconstruction in extended margin cancer surgery (REMACS) pancreatic cancer research and development and model trial.

16. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 March 2023.